As­traZeneca col­lab­o­rates with Myr­iad Ge­net­ics for can­cer ther­apy

BioSpectrum (Asia) - - Company News -

As­traZeneca is work­ing in col­lab­o­ra­tion with the molec­u­lar di­ag­nos­tics firm Myr­iad Ge­net­ics’ for its test myChoice HRD Plus to iden­tify ad­vanced ovar­ian can­cer pa­tients who might ben­e­fit from main­te­nance treat­ment us­ing Lyn­parza (ola­parib) and Avastin (be­va­cizumab). The new deal is part of an on­go­ing col­lab­o­ra­tion formed by the firm with As­traZeneca in 2007 for the de­vel­op­ment of a com­pan­ion di­ag­nos­tic test to de­tect in­di­vid­u­als for treat­ment with ola­parib. myChoice HRD Plus is a com­pre­hen­sive ho­mol­o­gous re­com­bi­na­tion de­fi­ciency test for the de­tec­tion of loss of a tu­mour’s abil­ity to re­pair breaks in dou­ble-stranded DNA. The test in­cludes loss of het­erozy­gos­ity, telom­eric al­lelic im­bal­ance and largescale state tran­si­tion tech­nolo­gies, along with 90 ad­di­tional genes and molec­u­lar mark­ers. Myr­iad will use the myChoice HRD Plus test to as­sess pa­tients in an on­go­ing Phase III trial and iden­tify par­tic­i­pants with ho­mol­o­gous re­com­bi­na­tion de­fi­cien­cies (HRD). Lyn­parza (ola­parib) is an oral poly ADP-ri­bose poly­merase (PARP) in­hibitor for­mu­lated to ex­ploit tu­mour DNA dam­age re­sponse (DDR) path­way de­fi­cien­cies to de­stroy can­cer cells. The drug is be­ing co-de­vel­oped and co-com­mer­cialised by As­traZeneca and Merck un­der a global strate­gic on­col­ogy al­liance signed in July last year.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.